palbociclib
UkraineDrugs containing this active substance
-
The drug is intended for the treatment of hormone receptor-positive (HR-positive) and HER2 receptor-negative breast cancer (locally advanced or metastatic). It is used in combination with aromatase inhibitors or in combination with fulvestrant.
Form: tablets, film-coated
Active substance Dosage palbociclib 75 mg ATC: L01EF01
Manufacturer: Synthon Hispania, S.L. (manufacturing, primary, secondary packaging, quality control, batch release)
-
The drug is intended for the treatment of hormone receptor-positive (HR-positive) and HER2-negative locally advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or in combination with fulvestrant (for women who have previously received endocrine therapy).
Form: tablets, film-coated
Active substance Dosage palbociclib 100 mg ATC: L01EF01
Manufacturer: Synthon Hispania, S.L. (manufacturing, primary, secondary packaging, quality control, batch release)
-
The drug is intended for the treatment of hormone receptor-positive (HR-positive) and HER2-negative locally advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or in combination with fulvestrant (for women who have previously received endocrine therapy).
Form: tablets, film-coated
Active substance Dosage palbociclib 125 mg ATC: L01EF01
Manufacturer: Synthon Hispania, S.L. (manufacturing, primary, secondary packaging, quality control, batch release)